http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2769312-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cbca833b926cb78b5a6178e9c3d613f4 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-328 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-521 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-747 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23C9-1234 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-747 |
| filingDate | 2017-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c2f1a177ef9d2c24684aa22c8edb6ce |
| publicationDate | 2022-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2769312-C2 |
| titleOfInvention | Use of lactic acid bacteria for treating or preventing gestational diabetes mellitus |
| abstract | FIELD: medicine; pharmaceutics.SUBSTANCE: group of inventions can be used to treat or prevent gestational diabetes mellitus (GDM) or one or more risks or complications associated with GDM. For this purpose, methods of treating or preventing gestational diabetes mellitus (GDM) in an adult female or in a subject, representing a fetus in the womb, newborn, infant or child, where the method involves the introduction of an effective amount of the strain Lactobacillus rhamnosus HN001, deposited in AGAL on August 18, 97 under number NM97/09514, to an adult female subject in need thereof or a pregnant mother of a fetus in the womb, a newborn, an infant or a child in need thereof, during pregnancy. Group of inventions also relates to the use of an effective amount of said strain in the manufacture of a formulation or drug for treating or preventing GDM.EFFECT: reducing the average fasting blood glucose level in the subject or the subject's pregnant mother to less than approximately 4,35 mmol/l.43 cl, 3 dwg, 4 tbl |
| priorityDate | 2016-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 134.